We will discuss your project and your needs with you. We can communicate either using a project form or by arranging a call
We will discuss your project and your needs with you. We can communicate either using a project form or by arranging a call –or several if needed-. What is important here is to make sure that we cover all your requirements for the planned experiments, including appropriate control vectors. Once your vectors’ desired genetic functions and components have been correctly defined, we will issue a quote based on these specific requirements.
Upon acceptance of our quote and placing of a formal order, we will initiate the in-silico design to generate predictive sequences and maps of your proposed vectors. These design will be based on the technology we use to assemble DNA fragment. Again, we will ask you to validate these complete sequences and features before moving to the production step. Step 1 of the process can take from a couple of days to a couple of weeks depending on the complexity of your project. We will always aim to be as reactive as possible.
Right after your approval of the predicted sequences, we will acquire all the physical elements required (oligonucleotides, synthetic genes, ORF clones, client’s DNA template etc.). Once we have generated all the necessary DNA bricks that will comprise your molecules, the vectors will be assembled in a one-step, one-tube reaction, then amplified in bacteria using classical molecular biology protocols. The amplified and purified vectors will then be validated using restriction mapping, and, if agreed upon, Sanger’s sequencing. Our production turnover can be very fast (sometimes as few as 3–5 days) but this varies depending on several parameters, such as the complexity of your molecules. A standard turnaround time would be 4–8 weeks, including the set-up and sequencing phases.
Because every project is unique and because DNA molecules never behave alike, it sometimes takes a little longer to obtain the desired molecules. However, when challenged by such unexpected hurdles, we adapt our assembly strategy to always allow us to deliver the expected molecules to our scientist customers. This is our commitment.
As a French company, we comply with the French regulatory laws applying to biotechnologies and routinely liaise with the relevant authorities to ensure this compliance.